Home LiteratureArticle Details
PMID: 6225118 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.

Pangburn MK, Schreiber RD, Müller-Eberhard HJ

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia in which the erythrocytes are abnormally sensitive to lysis by complement. A functional deficiency of membrane-associated complement regulators has been demonstrated on PNH erythrocytes. The two factor H-like proteins, the C3b receptor (CR1) and the decay-accelerating factor (DAF), were isolated from normal human erythrocytes, and specific antisera were prepared. Selective inhibition of the two proteins on normal erythrocytes by the antisera demonstrated (i) that the factor responsible for accelerated decay of erythrocyte-bound C3 convertase is DAF and (ii) that the cofactor required for inactivation of erythrocyte-bound C3b by factor I is CR1. PNH erythrocytes were deficient in both of these activities. Erythrocytes deficient in CR1, which were obtained from an apparently healthy individual, exhibited normal DAF activity but no factor I cofactor activity. These cells were not susceptible to complement-mediated lysis in acidified human serum, whereas PNH erythrocytes and Pronase-treated human erythrocytes (which lack DAF and CR1 activities) were lysed by this treatment. It is suggested that the protein primarily responsible for preventing complement activation on normal human erythrocytes is DAF. AMr 73,000 protein isolated from the normal erythrocyte membranes of one PNH patient by using anti-DAF IgG was largely absent from the abnormal erythrocytes of this individual, suggesting that PNH cells lack the DAF protein. CR1 antigen, however, was present on the abnormal PNH erythrocytes. The results suggest that the primary molecular defect underlying the clinical manifestations of PNH may be the lack of the membrane-associated DAF protein and that the abnormal cells may also exhibit impaired CR1 function.

MeSH Terms
Complement Activating Enzymes/metabolism Complement C3-C5 Convertases/metabolism Erythrocyte Membrane/metabolism Erythrocytes/metabolism Hemoglobinuria, Paroxysmal/genetics Humans Kinetics Membrane Proteins/deficiency,metabolism Molecular Weight Receptors, Complement/genetics,metabolism Receptors, Complement 3b Reference Values
Chemicals
Membrane Proteins Receptors, Complement Receptors, Complement 3b Complement Activating Enzymes Complement C3-C5 Convertases
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Pangburn M K
Schreiber R D
Müller-Eberhard H J
References (37)
37 references, click to expand
  1. Lysis of erythrocytes by complement in the absence of antibody.
    J Exp Med. 1970 Nov;132(5):898-915 PMID: 5470509
  2. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte.
    J Exp Med. 1980 Jul 1;152(1):20-30 PMID: 6967510
  3. Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system.
    N Engl J Med. 1972 Jan 27;286(4):180-4 PMID: 5007123
  4. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.
    J Exp Med. 1980 Oct 1;152(4):1102-14 PMID: 6903192
  5. Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies.
    J Immunol. 1981 Feb;126(2):693-8 PMID: 7005341
  6. Large scale isolation of functionally active components of the human complement system.
    J Biol Chem. 1981 Apr 25;256(8):3995-4006 PMID: 6783652
  7. Complement receptor is an inhibitor of the complement cascade.
    J Exp Med. 1981 May 1;153(5):1138-50 PMID: 6910481
  8. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    J Exp Med. 1981 Sep 1;154(3):856-67 PMID: 6912277
  9. Selective inhibition of functional sites of cell-bound C3b by hybridoma-derived antibodies.
    J Immunol. 1982 Jan;128(1):512-4 PMID: 6915074
  10. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    J Clin Invest. 1982 Feb;69(2):337-46 PMID: 6915939
  11. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
    J Immunol. 1982 Jul;129(1):184-9 PMID: 6211481
  12. Kinetics of interaction of immune complexes with complement receptors on human blood cells: modification of complexes during interaction with red cells.
    Clin Exp Immunol. 1982 Jun;48(3):715-25 PMID: 7116690
  13. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity.
    J Immunol. 1982 Nov;129(5):2051-60 PMID: 6214588
  14. Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of Beta 1H and is accompanied by generation of C3c.
    Proc Natl Acad Sci U S A. 1982 Aug;79(16):5047-51 PMID: 6214790
  15. On the lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by complement: dual role of C3b.
    Blut. 1982 Oct;45(4):249-59 PMID: 7126880
  16. Activation of complement via the alternative pathway.
    Fed Proc. 1983 Jan;42(1):139-43 PMID: 6217084
  17. Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.
    J Exp Med. 1983 Jun 1;157(6):1971-80 PMID: 6222136
  18. C3 convertase of the alternative complement pathway. Demonstration of an active, stable C3b, Bb (Ni) complex.
    J Biol Chem. 1983 Jun 25;258(12):7411-5 PMID: 6553050
  19. The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria.
    J Clin Invest. 1956 May;35(5):453-7 PMID: 13319478
  20. Inhibition of complement by a substance isolated from human erythrocytes. II. Studies on the site and mechanism of action.
    Immunochemistry. 1969 May;6(3):405-19 PMID: 5786934
  21. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.
    J Immunol. 1969 Nov;103(5):944-52 PMID: 4981797
  22. C3 proactivator convertase and its mode of action.
    J Exp Med. 1972 Apr 1;135(4):1003-8 PMID: 4111773
  23. Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells.
    J Clin Invest. 1973 May;52(5):1129-37 PMID: 4700488
  24. The organization of proteins in the human red blood cell membrane. A review.
    J Cell Biol. 1974 Jul;62(1):1-19 PMID: 4600883
  25. Continuous cultures of fused cells secreting antibody of predefined specificity.
    Nature. 1975 Aug 7;256(5517):495-7 PMID: 1172191
  26. The immune adherence receptor: dissociation between the expression of erythrocyte and mononuclear cell C3b receptors.
    J Immunol. 1975 Nov;115(5):1312-5 PMID: 1100727
  27. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
    J Exp Med. 1975 Sep 1;142(3):760-72 PMID: 1165475
  28. Control of the amplification convertase of complement by the plasma protein beta1H.
    Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72 PMID: 1067618
  29. Modulation of the alternative complement pathways by beta 1 H globulin.
    J Exp Med. 1976 Nov 2;144(5):1147-63 PMID: 62817
  30. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.
    J Exp Med. 1977 Jul 1;146(1):257-70 PMID: 301546
  31. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Proc Natl Acad Sci U S A. 1978 May;75(5):2416-20 PMID: 276881
  32. Paroxysmal nocturnal haemoglobinuria in aplastic anaemia.
    Clin Haematol. 1978 Oct;7(3):541-53 PMID: 363327
  33. The alternative pathway C3/C5 convertase: chemical basis of factor B activation.
    J Immunol. 1979 Aug;123(2):529-34 PMID: 458145
  34. Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b.
    J Immunol. 1980 Feb;124(2):977-82 PMID: 7356723
  35. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71 PMID: 293688
  36. Inhibitors of complement derived from the erythrocyte membrane in paroxysmal nocturnal hemoglobinuria.
    Blood. 1980 May;55(5):772-6 PMID: 7362868
  37. The C3-activator system: an alternate pathway of complement activation.
    J Exp Med. 1971 Sep 1;134(3 Pt 2):90s-108s PMID: 4105810
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
1983-09-00
Pages
5430-4
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC384270
Subset
IM
Grants
NIAID NIH HHS · AI-17354 · United States
NCI NIH HHS · CA-27490 · United States
NHLBI NIH HHS · HL-07195 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]